Volume 3.14 | Apr 14

Mammary Cell News 3.14 April 14, 2011
     In this issue: Science News | Current Publications | Industry News | Policy News | Events
Tiny Antibody Fragments Raised in Camels Find Drug Targets in Human Breast Cancer Cells
A new discovery promises to help physicians identify patients most likely to benefit from breast cancer drug therapies. [Press release from ScienceDaily discussing online prepublication in The FASEB Journal]

Soy Foods Not a Risk for Breast Cancer Survivors
A large new study found that eating soy foods did not increase the risk of cancer recurrence or death among breast cancer survivors. [Press release from Vanderbilt University discussing data presented at the American Association for Cancer Research Annual Meeting]

UMass Amherst Study Suggests Breast Milk May Offer a More Accurate and Personalized Indicator of Breast Cancer Risk
Early results of a study suggest that in the future, women and their physicians may have a new tool for evaluating breast cancer risk by examining epithelial cells naturally present in breast milk. [Press release from the University of Massachusetts, Amherst (UMass Amherst) discussing data presented at the American Association for Cancer Research 102nd Annual Meeting]

CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

CCL18 from Tumor-Associated Macrophages Promotes Breast Cancer Metastasis Via PITPNM3
Scientists show that breast tumor-associated macrophages abundantly produce CCL18, and its expression in blood or cancer stroma is associated with metastasis and reduced patient survival. [Cancer Cell]

Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer
The purpose of this study is to explore the prognostic value of tumor-infiltrating CD8+ cytotoxic lymphocytes in breast cancer. [J Clin Oncol]

Targeting p21-Activated Kinase 1 (PAK1) to Induce Apoptosis of Tumor Cells
To better understand the role of PAK1 in tumorigenesis, PAK1 genomic copy number and expression were determined for a large panel of breast, lung, and head and neck tumors. [Proc Natl Acad Sci USA]

Genome-Wide Functional Screen Identifies a Compendium of Genes Affecting Sensitivity to Tamoxifen
Investigators used a genome-wide functional profiling approach to identify multiple genes that confer resistance or sensitivity to tamoxifen. [Proc Natl Acad Sci USA]

Anti–ErbB-2 mAb Therapy Requires Type I and II Interferons and Synergizes with Anti–Programmed Death-1 or Anti-41BB mAb Therapy
Scientists report here that anti–human epidermal growth factor receptor-2 (ErbB-2) mAb therapy is dependent on the release of type I and type II interferons but is independent of perforin or FasL. [Proc Natl Acad Sci USA]

Luminal Expression of PIK3CA Mutant H1047R in the Mammary Gland Induces Heterogeneous Tumors
Researchers demonstrate that expression of mutant PIK3CA H1047R in the luminal mammary epithelium evokes heterogeneous tumors that express luminal and basal markers and are positive for the estrogen receptor. [Cancer Res]

ErbB3 Ablation Impairs Phosphatidylinositol 3-Kinase (PI3K)/AKT-Dependent Mammary Tumorigenesis
Investigators report that ErbB3 is critical for PI3K/AKT-driven tumor formation triggered by the polyomavirus middle T oncogene. [Cancer Res]

Orthodenticle Homolog 1 Gene Expression in Breast Cancer Is Regulated by p53
In this study, 28 human breast carcinomas have been analyzed for expression of wild-type p53 and of a pool of non-clustered homeobox genes. [Oncogene]

Loss of AF6/Afadin, a Marker of Poor Outcome in Breast Cancer, Induces Cell Migration, Invasiveness and Tumor Growth
To determine the role of afadin in breast cancer, scientists studied the functional consequences of afadin protein extinction using in vitro and in vivo models. [Oncogene

ARF1 Controls Proliferation of Breast Cancer Cells by Regulating the Retinoblastoma Protein
Findings provide direct physiological and molecular evidence for the role of ADP-ribosylation factors (ARF1) in controlling cell proliferation, dependent on its ability to regulate retinoblastoma protein/E2F1 activity and gene expression for enhanced proliferation and breast cancer progression. [Oncogene]

Preclinical Screening of Anti-HER2 Nanobodies for Molecular Imaging of Breast Cancer
Researchers describe the generation of a panel of 38 nanobodies, small human epidermal growth factor receptor 2 (HER2)-binding fragments that are derived from heavy-chain-only antibodies raised in an immunized dromedary. [FASEB J]

Disulfiram Modulated Reactive Oxygen Species–MAPK and NFκB Pathways and Targeted Breast Cancer Cells with Cancer Stem Cell-Like Properties
Disulfiram/copper inhibited breast cancer stem cells and enhanced cytotoxicity of paclitaxel in breast cancer cell lines. This may be caused by simultaneous induction of reactive oxygen species and inhibition of NFκB. [Br J Cancer]


Validation of a Novel Staging System for Disease-Specific Survival in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy
Investigators previously described a novel breast cancer staging system for assessing prognosis after neoadjuvant chemotherapy on the basis of pretreatment clinical stage (CS), estrogen receptor status (E), grade (G), and post-treatment pathologic stage (PS). This clinical-pathologic stage + EG staging system assigned and summed points for each factor, allowing for better determination of breast cancer–specific survival than CS or PS alone. [J Clin Oncol]

Topology Based Data Analysis Identifies a Subgroup of Breast Cancers with a Unique Mutational Profile and Excellent Survival
This article introduces a method that extracts information from high-throughput microarray data and, by using topology, provides greater depth of information than current analytic techniques. [Proc Natl Acad Sci USA]
First Patients to Receive New Cancer Drug
The Institute of Cancer Research is pleased to announce that an experimental drug it helped discover has started Phase I safety testing in patients with a range of cancer types. [The Institute of Cancer Research Press Release]

Key Findings in Cancer Biomarker Expression Highlighted at 2011 Annual Meeting of the American Association for Cancer Research
Caris Life Sciences, Inc. presented clinical data that validated the potential diagnostic impact of new biomarker profiles in combating breast cancer. [Caris Life Sciences, Inc. Press Release]

Rays of Hope Gift of $1.5 Million Establishes New Breast Cancer Research Center at PVLSI
The Pioneer Valley Life Sciences Institute (PVLSI) has received $1.5 million from the Rays of Hope Walk Toward the Cure of Breast Cancer to establish a new center devoted to breast cancer research. [University of Massachusetts Amherst Press Release]

FDA Requests Additional Information from Imaging Diagnostic Systems
Imaging Diagnostic Systems, Inc., announced that it has received notification from the Food and Drug Administration (FDA) requesting additional information of its 510 (k) application in order to complete their review. [Businesswire]
NICE Consults on New Breast Cancer Draft Quality Standard
National Institute for Health and Clinical Excellence (NICE) has launched a consultation on its draft quality standard for the management of patients with early, locally advanced and advanced breast cancer. [National Institute for Health and Clinical Excellence, United Kingdom]

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW European Molecular Biology Organization – Cancer Proteomics 2011 Systems Biology, Developmental Models & Data Integration
June 20-23, 2011
Dublin, Ireland

NEW Breast Cancer Symposium 2011
September 8-10, 2011
San Francisco, United States

Visit our events page to see a complete list of events in the mammary cell community.

Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Post-doctoral Fellow (University of Texas Medical School at Houston) 

PhD Program – Tumor Cell Intrinsic Signaling Pathways that Regulate Immune Suppression (Lady Davis Institute of Medical Research)

Post-doctoral Fellow (New Jersey Medical School, University of Medicine and Dentistry of New Jersey)

Post-doctoral Position in Cancer Research (Tufts Medical Center)

Post-doctoral Fellow in Gene Expression/Cancer and Stem Cell Biology (University of Cincinnati College of Medicine)

Post-doctoral Research Associate (University of Wisconsin – Madison)

Post-doctoral Fellow (University of Texas Medical School at Houston)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives | Events | Contact Us